Polskie Centrum Badań i Rozwoju Spółka z Ograniczoną Odpowiedzialnością (KRS 0000570164, NIP 9721256562) is a Polish company, headquartered in Poznań, Wielkopolskie voivodeship. Polskie Centrum Badań i Rozwoju operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since August 5, 2015.
Historical suspension of activities
Suspension: December 31, 2019 - resumed: January 1, 2022
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Polskie Centrum Badań i Rozwoju
Identity
- Name
- Polskie Centrum Badań i Rozwoju Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- Limited Liability Company (LLC)
- Founded
- August 5, 2015
- Registry status as of
- July 27, 2026
- Latest entry
- July 27, 2026
- Founding act
- 03.08.2015 R.
Articles of association history (2)
- August 3, 2015: 03.08.2015 R.
- April 21, 2016: 21.04.2016 R., REP. A NR 2185/2016, NOTARIUSZ ELŻBIETA HAŁACZKIEWICZ, KANCELARIA NOTARIALNA W POZNANIU PRZY AL. MARCINKOWSKIEGO 15/5 - PRZYJĘTO NOWY TEKST UMOWY SPÓŁKI 15.06.2016 R., REP. A NR 3500/2016, NOTARIUSZ ELŻBIETA HAŁACZKIEWICZ, KANCELARIA NOTARIALNA W POZNANIU PRZY AL. MARCINKOWSKIEGO 15/5 - PRZYJĘTO NOWY TEKST UMOWY SPÓŁKI
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. JULIUSZA SŁOWACKIEGO, 55, 1, 60-521, POZNAŃ, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- POZNAŃ
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Operational status - Polskie Centrum Badań i Rozwoju
Founded
August 5, 2015
11 years in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
POZNAŃ
WIELKOPOLSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
5.0 K PLN
100 shares total
Shareholders
1
shareholder
Board
1 person
Registry entries
26
latest: July 27, 2026
No KPI data - financial statements and valuation are unavailable for this company.
Board and connected people - Polskie Centrum Badań i Rozwoju
People holding roles at Polskie Centrum Badań i Rozwoju according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
- Cezary Piotr ZiarkowskiPresident of the board
- Marta Ewa ŻminkowskaPresident of the board
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - Polskie Centrum Badań i Rozwoju.
No ratings
Related articles
Explainer
Mabion in 2026: Polish monoclonal-antibody maker, mWIG40 issuer from Konstantynów Łódzki, Novavax COVID-19 antigen contract
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.
Explainer
Ryvu Therapeutics in 2026: a Kraków oncology biotech, RVU120 in Phase II clinical trials, a six-member management board, an mWIG40 issuer after the Selvita spin-off
Ryvu Therapeutics S.A. (KRS 0000367359), headquartered at ul. Leona Henryka Sternbacha 2 in Kraków, is a Polish oncology biotech developing anti-cancer small-molecule drugs. It has operated as a stand-alone company since the 2019 spin-off from Selvita (which retained the R&D-services business). Flagship project: RVU120 – a CDK8/19 kinase inhibitor in Phase II trials across multiple oncological indications. Listed on the WSE since 2019 and an mWIG40 constituent, with a six-member management board and a seven-member supervisory board.